BS_10APZRVT
Meningioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Meningioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Meningioma
- overall_survival_months
- 194.94086727989486
- age_years
- 14.879
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.448
- PROTEIN_SECRETION+0.409
- INTERFERON_GAMMA_RESPONSE+0.394
- ALLOGRAFT_REJECTION+0.379
- APOPTOSIS+0.286
- UV_RESPONSE_DN+0.285
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.279
- UNFOLDED_PROTEIN_RESPONSE+0.276
- IL6_JAK_STAT3_SIGNALING+0.273
- ANDROGEN_RESPONSE+0.265
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.428
- G2M_CHECKPOINT-0.404
- E2F_TARGETS-0.357
- MITOTIC_SPINDLE-0.249
- WNT_BETA_CATENIN_SIGNALING-0.237
- MYC_TARGETS_V2-0.215
- SPERMATOGENESIS-0.201
- PANCREAS_BETA_CELLS-0.189
- CHOLESTEROL_HOMEOSTASIS-0.180
- KRAS_SIGNALING_DN-0.088
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_JGPR9SR2 | Meningioma | — | 0.922 |
| 2 | BS_53CTGDQG | Meningioma | — | 0.905 |
| 3 | BS_KF0ZXDER | Meningioma | — | 0.871 |
| 4 | BS_E3EJHXQV | low-grade glioma | — | 0.851 |
| 5 | BS_W72364MN | Meningioma | — | 0.849 |
| 6 | BS_J60G8DMK | Meningioma | — | 0.845 |
| 7 | BS_H3Y8FWHV | Schwannoma | — | 0.842 |
| 8 | BS_SQX5E15Z | pilocytic astrocytoma | — | 0.842 |
| 9 | BS_1SVVER1H | Schwannoma | — | 0.838 |
| 10 | DRR168598 | — | — | 0.818 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.448 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.409 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.394 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.379 | Idelalisib | — uncovered |
| APOPTOSIS | 0.286 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.285 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.279 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.276 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.273 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.265 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.261 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.246 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.217 | Inavolisib | — uncovered |
| COMPLEMENT | 0.215 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.213 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.207 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.206 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.195 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.194 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.185 | Inavolisib | — uncovered |